Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease

被引:413
|
作者
Micha, Renata [1 ]
Imamura, Fumiaki [1 ]
von Ballmoos, Moritz Wyler [2 ,3 ]
Solomon, Daniel H. [4 ,5 ]
Hernan, Miguel A. [1 ,8 ]
Ridker, Paul M. [3 ,6 ,7 ]
Mozaffarian, Dariush [1 ,3 ,6 ,7 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[2] Childrens Hosp, Dept Cardiac Surg, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Brigham & Womens Hosp, Div Rheumatol, Boston, MA USA
[5] Brigham & Womens Hosp, Div Immunol & Allergy, Boston, MA USA
[6] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA USA
[7] Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA USA
[8] Harvard MIT Div Hlth Sci & Technol, Boston, MA USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2011年 / 108卷 / 09期
基金
美国国家卫生研究院;
关键词
LOW-DOSE METHOTREXATE; CORONARY-HEART-DISEASE; RHEUMATOID-ARTHRITIS; MYOCARDIAL-INFARCTION; PREDICTORS; MORTALITY; EVENTS; STROKE; TRIAL; BIAS;
D O I
10.1016/j.amjcard.2011.06.054
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Inflammation predicts risk for cardiovascular disease (CVD) events, but the relation of drugs that directly target inflammation with CVD risk is not established. Methotrexate is a disease-modifying antirheumatic drug broadly used for the treatment of chronic inflammatory disorders. A systematic review and meta-analysis of evidence of relations of methotrexate with CVD occurrence were performed. Cohorts, case-control studies, and randomized trials were included if they reported associations between methotrexate and CVD risk. Inclusions and exclusions were independently adjudicated, and all data were extracted in duplicate. Pooled effects were calculated using inverse variance-weighted meta-analysis. Of 694 identified publications, 10 observational studies in which methotrexate was administered in patients with rheumatoid arthritis, psoriasis, or polyarthritis met the inclusion criteria. Methotrexate was associated with a 21% lower risk for total CVD (n = 10 studies, 95% confidence interval [CI] 0.73 to 0.87, p <0.001) and an 18% lower risk for myocardial infarction (n = 5, 95% CI 0.71 to 0.96, p = 0.01), without evidence for statistical between-study heterogeneity (p = 0.30 and p = 0.33, respectively). Among prespecified sources of heterogeneity explored, stronger associations were observed in studies that adjusted for underlying disease severity (relative risk 0.64, 95% CI 0.43 to 0.96, p <0.01) and for other concomitant medication (relative risk 0.73, 95% CI 0.63 to 0.84, p <0.001). Publication bias was potentially evident (funnel plot, Begg's test, p = 0.06); excluding studies with extreme risk estimates did not, however, alter results (relative risk 0.81, 95% CI 0.74 to 0.89). In conclusion, methotrexate use is associated with a lower risk for CVD in patients with chronic inflammation. These findings suggest that a direct treatment of inflammation may reduce CVD risk. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011; 108:1362-1370)
引用
收藏
页码:1362 / 1370
页数:9
相关论文
共 50 条
  • [1] Use of smokeless tobacco and risk of cardiovascular disease: A systematic review and meta-analysis
    Vidyasagaran, Aishwarya L.
    Siddiqi, Kamran
    Kanaan, Mona
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2016, 23 (18) : 1970 - 1981
  • [2] Vasectomy and cardiovascular disease risk A systematic review and meta-analysis
    Guo, Zhen-Lang
    Xu, Jing-Li
    Lai, Ren-Kui
    Wang, Shu-Sheng
    [J]. MEDICINE, 2017, 96 (34)
  • [3] Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis
    Phung, O. J.
    Schwartzman, E.
    Allen, R. W.
    Engel, S. S.
    Rajpathak, S. N.
    [J]. DIABETIC MEDICINE, 2013, 30 (10) : 1160 - 1171
  • [4] Endometriosis and Risk of Cardiovascular Disease: Systematic Review and Meta-Analysis
    Okoli, Unoma
    Charoenngam, Nipith
    Ponvilawan, Ben
    Jaroenlapnopparat, Aunchalee
    Mettler, Sofia
    Obiejesie, Onyenma
    [J]. JOURNAL OF WOMENS HEALTH, 2023, 32 (12) : 1328 - 1339
  • [5] Peanut and cardiovascular disease risk factors: A systematic review and meta-analysis
    Azad, Banafsheh
    Daneshzad, Elnaz
    Azadbakht, Leila
    [J]. CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2020, 60 (07) : 1123 - 1140
  • [6] Sexual violence and cardiovascular disease risk: A systematic review and meta-analysis
    Jakubowski, Karen P.
    Murray, Vanessa
    Stokes, Natalie
    Thurston, Rebecca C.
    [J]. MATURITAS, 2021, 153 : 48 - 60
  • [7] α-Linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis
    Pan, An
    Chen, Mu
    Chowdhury, Rajiv
    Wu, Jason H. Y.
    Sun, Qi
    Campos, Hannia
    Mozaffarian, Dariush
    Hu, Frank B.
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2012, 96 (06): : 1262 - 1273
  • [8] Sexual Violence and Cardiovascular Disease Risk: A Systematic Review and Meta-Analysis
    Jakubowski, Karen P.
    Murray, Vanessa
    Stokes, Natalie
    Thurston, Rebecca C.
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2021, 28 (12): : 1450 - 1450
  • [9] Use of MHT in women with cardiovascular disease: a systematic review and meta-analysis
    Bontempo, S.
    Yeganeh, L.
    Giri, R.
    Vincent, A. J.
    [J]. CLIMACTERIC, 2024, 27 (01) : 93 - 103
  • [10] STATIN USE AND RISK OF DEVELOPING DIABETES IN CARDIOVASCULAR DISEASE: SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
    Thakker, D.
    Nair, S. R.
    Shukla, H.
    Shaikh, J. S.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A478 - A478